Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES DUSTIN AND ALTOR IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM
Mandate

VINGE ADVISES DUSTIN AND ALTOR IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

February 17, 2015

Vinge advises Dustin Group AB (publ) and Altor in connection with Dustin’s listing on Nasdaq Stockholm.

Dustin is a leading online based reseller of IT products and services in the Nordics. Dustin offers a wide product and service range to businesses, public organisations and consumers, primarily through its online platform. The Swedish language prospectus was published on 2 February 2015 and the first day of trading was 13 February 2015. The offering price has been set at SEK 50 per share, corresponding to a market value of Dustin of approximately SEK 3,809 million.
Vinge’s team primarily consisted of Peter Bäärnhielm, David Andersson, Sabina Börjesson, Amanda Knutsson and Tora Hansjons.

Vinge företräder Dustin och Altor i samband med börsnoteringen på Nasdaq Stockholm

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026